Figure 6.
Figure 6. Blockade of FcγRII on iMDDCs decreases HIV-inhibitory activity of polyclonal IgG sample no. 8 or neutralizing monoclonal IgG 2F5. Purified mouse monoclonal IgG1κ (10 μg/mL) directed against each human FcγRI, FcγRII, FcγRIII, or combined was added on iMDDCs (A,B,E) or PHA-stimulated PBMCs (C-D) 30 minutes prior to infection with HIV-1BaL-IgG ICs. The percentages of infected cells in the presence of purified IgG (A,C) or IgA sample no. 8 (E) or monoclonal IgG 2F5 (B,D) were determined. Values are the mean ± SD of 3 independent wells from one representative experiment.

Blockade of FcγRII on iMDDCs decreases HIV-inhibitory activity of polyclonal IgG sample no. 8 or neutralizing monoclonal IgG 2F5. Purified mouse monoclonal IgG1κ (10 μg/mL) directed against each human FcγRI, FcγRII, FcγRIII, or combined was added on iMDDCs (A,B,E) or PHA-stimulated PBMCs (C-D) 30 minutes prior to infection with HIV-1BaL-IgG ICs. The percentages of infected cells in the presence of purified IgG (A,C) or IgA sample no. 8 (E) or monoclonal IgG 2F5 (B,D) were determined. Values are the mean ± SD of 3 independent wells from one representative experiment.

Close Modal

or Create an Account

Close Modal
Close Modal